Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1066 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-01-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.09 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 29.84 | Oscillator | Neutral |
| Williams %R (14) | -67.62 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.05 (Hist -0.05) | Oscillator | Strong Sell |
| Average Directional Index (14) | 15.47 (+DI 25.1 / -DI 20.8) | Trend | Neutral |
Current price $12.58
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Nov 12, 25 |
| EMA 20 | 12.70 | MA | Sell |
| SMA 20 | 12.79 | MA | Sell |
| EMA 50 | 12.39 | MA | Buy |
| SMA 50 | 12.74 | MA | Sell |
| SMA 200 | 8.32 | MA | Strong Buy |
| Cantor Fitzgerald |
| downgrade |
| Overweight |
| Neutral |
| Oct 16, 25 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Oct 15, 25 | JMP Securities | downgrade | Market Outperform | Market Perform |
| Oct 15, 25 | Wedbush | downgrade | Outperform | Neutral |
| Oct 14, 25 | Jefferies | downgrade | Buy | Hold |
| Sep 17, 25 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 17, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 13, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 13, 25 | JMP Securities | maintain | Market Outperform | Market Outperform |
Stock news · updated daily
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Nov 12, 2025 | -0.41 | -0.55 | Miss -34.1% | $706.0K |
| Aug 12, 2025 | -0.61 | -0.57 | Beat 6.6% | — |
| May 13, 2025 | -0.48 | -0.58 | Miss -20.8% | — |
| Mar 11, 2025 | -0.45 | -0.44 | Beat 2.2% | — |
| Nov 13, 2024 | -0.42 | -0.42 | Beat 0.0% | — |
| Aug 12, 2024 | -0.37 | -0.43 | Miss -16.2% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jan 23, 26 | Violin Jonathan | director | D-Return | 14,100 @ $11.35 | $160.0K |
| Jan 23, 26 | Violin Jonathan | director | D-Return | 8,333 @ $3.00 | $25.00K |
| Jan 23, 26 | Violin Jonathan | director | D-Return | 14,100 @ $9.18 | $129.4K |
| Jan 23, 26 | Violin Jonathan | director | D-Return | 263,321 | — |
| Jan 23, 26 | Violin Jonathan | director | D-Return | 14,166 @ $12.24 | $173.4K |
| Jan 23, 26 | Violin Jonathan | director | D-Return | 26,550 @ $5.79 | $153.7K |
| Jan 23, 26 | Morabito Christopher | officer: Chief Medical Officer | D-Return | 80,000 @ $3.87 | $309.6K |
| Jan 23, 26 | Morabito Christopher | officer: Chief Medical Officer | D-Return | 262,500 @ $6.41 | $1.68M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ATXS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -11.2x | -2.8x · sector 20.7x | Discount |
| Forward P/E (FY25E) | -6.3x | EPS est. -1.99 | Discount |
| Price / Book | 3.1x | 1.0x | Elevated |
| Price / Sales | 1017.2x | — | n/a |
| EV / EBITDA | -9.7x | -1.7x | Elevated |
| Return on equity | -26.2% | — | Weak |
| Gross margin | 100.0% | 0.0% | n/a |
| Debt / Equity | 0.02 | 0.01 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 6.69 | Safe zone |
Discounted cash flow model
| SC 13D/A | Jan 28, 2026 | 2026-01-28 08:38:48 | View |
| EFFECT | Jan 27, 2026 | 2026-01-28 00:15:11 | View |
| EFFECT | Jan 27, 2026 | 2026-01-28 00:15:10 | View |
| EFFECT | Jan 27, 2026 | 2026-01-28 00:15:07 | View |
| EFFECT | Jan 27, 2026 | 2026-01-28 00:15:06 | View |
| EFFECT | Jan 27, 2026 | 2026-01-28 00:15:05 | View |
Proxy statement (DEF 14A) disclosures